Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

The Oncologist, Vol. 9, No. 6, 653-664, November 2004; doi:10.1634/theoncologist.9-6-653
© 2004 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grover, A.
Right arrow Articles by Alexander, H. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grover, A.
Right arrow Articles by Alexander, H. R., Jr.

The Past Decade of Experience With Isolated Hepatic Perfusion

Amelia Grover, H. Richard Alexander, Jr.

Surgical Metabolism Section, Surgery Branch, Center for Cancer Research National Cancer Institute, Bethesda, Maryland, USA

Correspondence: H. Richard Alexander, Jr., M.D., Head, Surgical Metabolism Section, National Cancer Institute/NIH, 10 Center Drive, Building 10, Room 2B07, Bethesda, Maryland 20892-1502, USA. Telephone: 301-496-2195; Fax: 301-402-1788; e-mail: Richard_Alexander{at}nih.gov

Metastatic or primary unresectable cancers confined to the liver are the sole or life-limiting component of disease for many patients with colorectal cancer, ocular melanoma, neuroendocrine tumors, or primary colangio- or hepatocellular carcinomas. Regional treatment strategies including infusional chemotherapy and local ablative therapy are under investigation, but have limitations with respect to the clinical conditions under which they can be employed. Isolated hepatic perfusion (IHP) was first clinically applied over 40 years ago, but because of its technical complexity, the attendant potential morbidity, and the lack of documented efficacy, it has not enjoyed consistent or widespread evaluation. In light of the antitumor activity with isolated limb perfusion with tumor necrosis factor (TNF) and melphalan in patients with unresectable extremity sarcoma or in transit melanoma, this regimen has been administered via IHP at several centers worldwide for patients with unresectable liver cancers. IHP with TNF and melphalan can result in significant regression of advanced refractory cancers from multiple histologies confined to the liver. Patient selection is important to ensure good results with minimal morbidity and mortality. Work to define the appropriate clinical groups is ongoing at many clinical centers.

Key Words. Liver metastases • Primary hepatic neoplasms • Colorectal cancer • Ocular melanoma • Isolation perfusion • Regional chemotherapy • Hyperthermia




This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
K. V. Sharma, J. E. Gould, J. W. Harbour, G. P. Linette, T. K. Pilgram, P. N. Dayani, and D. B. Brown
Hepatic Arterial Chemoembolization for Management of Metastatic Melanoma
Am. J. Roentgenol., January 1, 2008; 190(1): 99 - 104.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2004 by AlphaMed Press.
Advertisement